Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9%Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bpsCash…
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology…
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program…
BRENTWOOD, Tenn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical…
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion…
Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024On track…
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex…
Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive…
BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the…
Toronto, Ontario--(Newsfile Corp. - August 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a…